Corveus Medical is developing a minimally-invasive device that deactivates a specific nerve associated with congestive heart failure, providing a new treatment option for patients with limited alternatives. This approach aims to improve patient quality of life by delivering consistent results and confirming procedure success through nerve removal.
Funding
$750K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with moderate heart failure often have limited treatment options, leading to a reduced quality of life. Current interventions may not consistently address the underlying nerve signals that contribute to the progression of the condition.
Solution
Corveus Medical is developing a minimally-invasive device designed to deactivate a specific nerve branch associated with congestive heart failure. The device aims to provide physicians with a reliable method for treating patients who have traditionally had few alternatives. By removing a branch of the problematic nerve and confirming successful removal during the procedure, the solution seeks to offer consistent results and durable benefits, ultimately improving the patient's quality of life.
Target Audience
The primary target audience includes physicians treating patients with moderate heart failure who are seeking effective and safe treatment options for their patients.
Features
- Minimally-invasive device for targeted nerve deactivation.
- Designed to remove a specific nerve branch contributing to heart failure.
- Intra-procedural confirmation of nerve removal to ensure success.
- Aims to provide consistent and durable results for patients.